Anti-contactin-associated protein-2 encephalitis: relevance of antibody titres, presentation and outcome

European Journal of Neurology

Volumn 24, Issue 1, 2017, Pages 175-186

  Bien, C G ^a   Mirzadjanova, Z ^a   Baumgartner, C ^b   Onugoren, M D ^a,c   Grunwald, T ^d   Holtkamp, M ^e   Isenmann, S ^f   Kermer, P ^g   Melzer, N ^h   Naumann, M ⁱ   Riepe, M ^j   Schabitz W R ^k   von Oertzen, T J ^l   von Podewils, F ^m   Rauschka, H ⁿ   May, T W ^a  

^a EPILEPSY CENTER BETHEL   (Germany)

^b SIGMUND FREUD UNIVERSITY   (Austria)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e Epilepsy Center Berlin Brandenburg   (Germany)

^f UNIVERSITY OF WITTEN HERDECKE   (Germany)

^g Nordwest Krankenhaus Sanderbusch   (Germany)

^h UNIVERSITY OF MÜNSTER   (Germany)

ⁱ KLINIKUM AUGSBURG   (Germany)

^j UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

^k EVANGELISCHES KRANKENHAUS   (Germany)

^l KEPLER UNIVERSITY HOSPITAL   (Austria)

^m UNIVERSITY MEDICINE GREIFSWALD   (Germany)

ⁿ DANUBE HOSPITAL   (Austria)

more..

Author keywords

autoimmune encephalitis; autoimmune epilepsy; contactin associated protein 2 antibodies; outcome

Indexed keywords

IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; AUTOANTIBODY; CNTNAP2 PROTEIN, HUMAN; MEMBRANE PROTEIN; NERVE PROTEIN;

ADULT; AGED; ANTI CONTACTIN ASSOCIATED PROTEIN 2 ENCEPHALITIS; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CEREBROSPINAL FLUID; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; ELECTROENCEPHALOGRAPHY; ENCEPHALITIS; FEMALE; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORVAN SYNDROME; MOTOR DYSFUNCTION; NATIONAL HEALTH ORGANIZATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARANEOPLASTIC NEUROPATHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BLOOD; DIAGNOSTIC IMAGING; IMMUNOLOGY; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

AGED; AUTOANTIBODIES; ENCEPHALITIS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84995910837     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.13180     Document Type: Article

References (29)

1. Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011; 10: 759–772.
2. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010; 133: 2734–2748.
3. Lancaster E, Huijbers MG, Bar V, et al. Investigations of Caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011; 69: 303–311.
4. Becker EB, Zuliani L, Pettingill R, et al. Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry 2012; 83: 437–440.
5. Krogias C, Hoepner R, Muller A, Schneider-Gold C, Schroder A, Gold R. Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab. JAMA Neurol 2013; 70: 1056–1059.
6. O'Toole O, Lennon VA, Ahlskog JE, et al. Autoimmune chorea in adults. Neurology 2013; 80: 1133–1144.
7. Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014; 13: 167–177.
8. Zandi MS, Paterson RW, Ellul MA, et al. Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes. J Neurol Neurosurg Psychiatry 2015; 86: 708–713.
9. Carvajal-Gonzalez A, Leite MI, Waters P, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain 2014; 137: 2178–2192.
10. Meinck HM, Faber L, Morgenthaler N, et al. Antibodies against glutamic acid decarboxylase: prevalence in neurological diseases. J Neurol Neurosurg Psychiatry 2001; 71: 100–103.
11. Zuliani L, Graus F, Giometto B, Bien C, Vincent A. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry 2012; 83: 638–645.
12. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391–404.
13. Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 2012; 72: 241–255.
14. Panzer J, Dalmau J. Movement disorders in paraneoplastic and autoimmune disease. Curr Opin Neurol 2011; 24: 346–353.
15. http://www.ninds.nih.gov/disorders/encephalopathy/encephalopathy.htm (accessed 02/05/2016).
16. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75: 1135–1140.
17. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091–1098.
18. Wandinger KP, Saschenbrecker S, Stoecker W, Dalmau J. Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol 2011; 231: 86–91.
19. Reiber H, Lange P. Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain. Clin Chem 1991; 37: 1153–1160.
20. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127: 701–712.
21. Sunwoo JS, Lee ST, Byun JI, et al. Clinical manifestations of patients with CASPR2 antibodies. J Neuroimmunol 2015; 281: 17–22.
22. Joubert B, Saint-Martin M, Noraz N, et al. Cerebrospinal fluid anti-CASPR2 antibodies determine a subtype of autoimmune encephalitis with prominent limbic symptoms and seizures. JAMA Neurol 2016; 73: 1115–1124.
23. Vincent A, Irani SR. Caspr2 antibodies in patients with thymomas. J Thorac Oncol 2010; 5(Suppl. 4): S277–S280.
24. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010; 133: 1655–1667.
25. van Sonderen A, Schreurs MW, de Bruijn MA, et al. The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies. Neurology 2016; 86: 1692–1699.
26. Graus F, Gorman MP. Voltage-gated potassium channel antibodies: game over. Neurology 2016; 86: 1657–1658.
27. Pettingill P, Kramer HB, Coebergh JA, et al. Antibodies to GABAA receptor alpha1 and gamma2 subunits: clinical and serologic characterization. Neurology 2015; 84: 1233–1241.
28. Körtvelyessy P, Bauer J, Stoppel CM, et al. Complement-associated neuronal loss in a patient with CASPR2 antibody-associated encephalitis. Neurol Neuroimmunol Neuroinflamm 2015; 2: e75.
29. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014; 55: 475–482.